AbbVie and Calico Life Sciences have officially terminated their 11-year research and development partnership focused on aging, as confirmed by a spokesperson from Calico. This collaboration, which began in 2014, aimed to leverage AbbVie’s pharmaceutical expertise alongside Calico’s innovative approaches to understanding the biology of aging.
The dissolution of this partnership raises questions about the future direction of the projects initiated under their collaboration. Calico has stated that it is now “fully resourced to assume full responsibility for all existing programs developed during the AbbVie collaboration,” indicating a strategic pivot as the company seeks to navigate its own path in the competitive landscape of aging research.
This separation could have significant implications for both companies. For AbbVie, it may signal a shift in focus towards other therapeutic areas, while Calico’s independence could lead to accelerated innovation as it seeks to capitalize on its findings without the constraints of a corporate partnership.
Get started today with Solo access →
